SUN PHARMA has announced its results for the quarter ended June 2019. Here is a detailed performance review of the same:
No. of Mths Qtr. Ending | 3 Jun-18* | 3 Mar-19* | 3 Jun-19* | QoQ Change | YoY Change | |
---|---|---|---|---|---|---|
Net Sales | Rs m | 72,242 | 71,639 | 83,744 | 16.9% | 15.9% |
Other income | Rs m | 1,998 | 2,815 | 2,130 | -24.3% | 6.6% |
Turnover | Rs m | 74,239 | 74,455 | 85,874 | 15.3% | 15.7% |
Expenses | Rs m | 56,175 | 61,471 | 63,788 | 3.8% | 13.6% |
Gross profit | Rs m | 16,067 | 10,168 | 19,956 | 96.3% | 24.2% |
Depreciation | Rs m | 4,016 | 4,541 | 4,571 | 0.7% | 13.8% |
Interest | Rs m | 1,309 | 1,500 | 1,041 | -30.6% | -20.5% |
Profit before tax | Rs m | 12,739 | 6,942 | 16,474 | 137.3% | 29.3% |
Tax | Rs m | 1,639 | -288 | 1,461 | -10.9% | |
Profit after tax | Rs m | 11,101 | 7,231 | 15,014 | 107.6% | 35.3% |
Gross profit margin | % | 22.2 | 14.2 | 23.8 | ||
Effective tax rate | % | 12.9 | -4.1 | 8.9 | ||
Net profit margin | % | 15.0 | 9.7 | 17.5 |
To see how SUN PHARMA has performed over the last eight quarters,please visit here.
Over the last one year,SUN PHARMA share price has moved down from Rs 601.7 to Rs 416.7, registering a Loss of Rs 185.0 or around 30.7%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,484.3 (down 0.7%). Over the last one year it has moved down from 14,687.0 to 12,484.3, a gain of 2,203 points (down 15.0%).
Overall, the S&P BSE SENSEX is down 0.6% over the year.
At the current price of Rs 416.7, the price to earnings (P/E) ratio of SUN PHARMA stands at 28.0 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.4 times.
Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More
| |
Equitymaster requests your view! Post a comment on "SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!